Muñoz N, Vivas J, Buiatti E, Kato I, Oliver W
Unit of Field and Intervention Studies, International Agency for Research on Cancer, Lyon, France.
IARC Sci Publ. 1996(139):125-33.
A double-blind, placebo-controlled trial is being conducted in a population at high risk for gastric cancer in Venezuela. The main aim of the trial is to assess the effect of antioxidant vitamins (beta-carotene, vitamin C and vitamin E) in blocking the progression of precancerous lesions of the stomach. Within the framework of a screening programme for stomach cancer, 2200 subjects of 35-69 years of age have been recruited. At study entry, a dietary questionnaire was completed, and gastroscopy with the collection of seven gastric biopsies was performed. After baseline examinations, the study participants were randomized to receive antioxidant treatment or placebo for three years. The treatment phase will be completed in mid-1998. At the end of the treatment phase, the investigations performed at study entry will be repeated. Before the initiation of the trial, various pilot studies were carried out that showed an extremely high prevalence of Helicobacter pylori infection (over 90%). Two eradication trials using anti-H. pylori treatments that give good results in Europe and North America gave very poor results in our study population. The low eradication rates achieved (5-20%) suggest a high prevalence of antibiotic-resistant H. pylori strains or high reinfection rates. These disappointing results led to deletion of an anti-H. pylori treatment phase of the main trial.
委内瑞拉正在对胃癌高危人群开展一项双盲、安慰剂对照试验。该试验的主要目的是评估抗氧化维生素(β-胡萝卜素、维生素C和维生素E)对阻断胃癌前病变进展的作用。在胃癌筛查项目框架内,招募了2200名35至69岁的受试者。在研究开始时,完成了一份饮食问卷,并进行了胃镜检查,采集了7份胃活检样本。在基线检查后,研究参与者被随机分为两组,接受为期三年的抗氧化治疗或安慰剂治疗。治疗阶段将于1998年年中完成。在治疗阶段结束时,将重复研究开始时进行的各项调查。在试验开始前,进行了多项试点研究,结果显示幽门螺杆菌感染率极高(超过90%)。两项使用抗幽门螺杆菌治疗的根除试验在欧洲和北美取得了良好效果,但在我们的研究人群中效果却很差。所达到的低根除率(5%至20%)表明,幽门螺杆菌对抗生素耐药菌株的患病率很高,或者再感染率很高。这些令人失望的结果导致主要试验中取消了抗幽门螺杆菌治疗阶段。